Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

J Duell; E Gonzalez-Barca; Marinela Augustin; W Jurczak; AM Liberati; S de Vos; Z Nagy; A Obr; G Gaidano; P Abrisqueta; N Kalakonda; M Andre; T Menne; O Tournilhac; EE Waltl; M Dirnberger-Hertweck; J Weirather; KJ Maddocks; S Ambarkhane; M Dreyling; G Salles

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

J Duell, E Gonzalez-Barca, Marinela Augustin, W Jurczak, AM Liberati, S de Vos, Z Nagy, A Obr, G Gaidano, P Abrisqueta, N Kalakonda, M Andre, T Menne, O Tournilhac, EE Waltl, M Dirnberger-Hertweck, J Weirather, KJ Maddocks, S Ambarkhane, M DreylingG Salles

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	63-64
Journal	Oncology Research and Treatment
Volume	43
Issue number	SUPPL 4
Publication status	Published - 2020

Cite this

Duell, J., Gonzalez-Barca, E., Augustin, M., Jurczak, W., Liberati, AM., de Vos, S., Nagy, Z., Obr, A., Gaidano, G., Abrisqueta, P., Kalakonda, N., Andre, M., Menne, T., Tournilhac, O., Waltl, EE., Dirnberger-Hertweck, M., Weirather, J., Maddocks, KJ., Ambarkhane, S., ... Salles, G. (2020). Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Oncology Research and Treatment, 43(SUPPL 4), 63-64.

@article{33c1d83c0ed444b6a0828eb974eb8281,

title = "Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma",

author = "J Duell and E Gonzalez-Barca and Marinela Augustin and W Jurczak and AM Liberati and {de Vos}, S and Z Nagy and A Obr and G Gaidano and P Abrisqueta and N Kalakonda and M Andre and T Menne and O Tournilhac and EE Waltl and M Dirnberger-Hertweck and J Weirather and KJ Maddocks and S Ambarkhane and M Dreyling and G Salles",

year = "2020",

language = "English",

volume = "43",

pages = "63--64",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

number = "SUPPL 4",

}

Duell, J, Gonzalez-Barca, E, Augustin, M, Jurczak, W, Liberati, AM, de Vos, S, Nagy, Z, Obr, A, Gaidano, G, Abrisqueta, P, Kalakonda, N, Andre, M, Menne, T, Tournilhac, O, Waltl, EE, Dirnberger-Hertweck, M, Weirather, J, Maddocks, KJ, Ambarkhane, S, Dreyling, M & Salles, G 2020, 'Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma', Oncology Research and Treatment, vol. 43, no. SUPPL 4, pp. 63-64.

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. / Duell, J; Gonzalez-Barca, E; Augustin, Marinela et al.
In: Oncology Research and Treatment, Vol. 43, No. SUPPL 4, 2020, p. 63-64.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

AU - Duell, J

AU - Gonzalez-Barca, E

AU - Augustin, Marinela

AU - Jurczak, W

AU - Liberati, AM

AU - de Vos, S

AU - Nagy, Z

AU - Obr, A

AU - Gaidano, G

AU - Abrisqueta, P

AU - Kalakonda, N

AU - Andre, M

AU - Menne, T

AU - Tournilhac, O

AU - Waltl, EE

AU - Dirnberger-Hertweck, M

AU - Weirather, J

AU - Maddocks, KJ

AU - Ambarkhane, S

AU - Dreyling, M

AU - Salles, G

PY - 2020

Y1 - 2020

M3 - Abstract (Journal)

SN - 2296-5270

VL - 43

SP - 63

EP - 64

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 4

ER -